Central nervous system (CNS) metastatic disease (unless controlled and stable for at least 4 weeks), leptomeningeal disease, or cord compression.

Clinically significant CNS dysfunction.

Any other active malignancy within 3 years prior to enrollment.

Prior treatment with anti-CD70 therapies.

Current thyroid disorder (including hyperthyroidism) with the exception of hypothyroidism controlled on stable dose of hormone replacement therapy.

Prior treatment with anti-CD52 monoclonal antibody in the past 12 months.

Participants unwilling to participate in the extended safety monitoring period.

Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma